UroToday

ESMO 2025: GETUG-AFU 43–PEACE8: Combination of Darolutamide and SBRT in Patients with CRPC and Oligometastases on Functional Imaging

As of September 2025, 15 patients have been recruited across 8 centers. Spain, Belgium, and Ireland, with 15 centers, will be open for inclusion in Q4 of 2025, with 9 more centers in France also being ...
UroToday

Trends in the Diagnoses of Subtype Histologies in Bladder Cancer - Expert Commentary

Wallace BK, Su ZT, Flynn JP, Garman TS, Weitzner A, Rezaee ME, et al. National trends in diagnoses of subtype histologies in bladder cancer: A population-based study based on the SEER database. Urol ...
UroToday

WSAUA 2025: Impact of Bone Protecting Agents on Outcomes with Enzalutamide, with or without Radium-223, in Asymptomatic/mildly Symptomatic Patients with Bone mCRPC from PEACE-3

Patients with bone-protecting agent use versus no bone-protecting agent had similar baseline characteristics: ...
UroToday

WSAUA 2025: Impact of Neoadjuvant Systemic Therapy on Tumor and Tumor Thrombus Regression in Renal Cell Carcinoma with Venous Involvement: A Retrospective Analysis

The 2025 Western Section AUA annual meeting featured a kidney cancer session and a presentation by Jaxson Jeffery discussing the impact of neoadjuvant systemic therapy on tumor and tumor thrombus ...